Search Results - "RUBIN, Eric H"

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors by Cristescu, Razvan, Aurora-Garg, Deepti, Albright, Andrew, Xu, Lei, Liu, Xiao Qiao, Loboda, Andrey, Lang, Lixin, Jin, Fan, Rubin, Eric H, Snyder, Alexandra, Lunceford, Jared

“…BackgroundSeveral studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II…”
Get full text

Drug development and clinical trials—the path to an approved cancer drug by Rubin, Eric H., Gilliland, D. Gary

“…The current system for the development of anticancer drugs is not fit for purpose. In this Review article, this system is examined from the perspective of the…”
Get full text

Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy by Nie, Lei, Rubin, Eric H, Mehrotra, Nitin, Pinheiro, José, Fernandes, Laura L, Roy, Amit, Bailey, Stuart, de Alwis, Dinesh P

“…Selection of the maximum tolerated dose (MTD) as the recommended dose for registration trials based on a dose-escalation trial using variations of an MTD/3 + 3…”
Get full text

Antitumor activity in RAS-driven tumors by blocking AKT and MEK by Tolcher, Anthony W, Khan, Khurum, Ong, Michael, Banerji, Udai, Papadimitrakopoulou, Vassiliki, Gandara, David R, Patnaik, Amita, Baird, Richard D, Olmos, David, Garrett, Christopher R, Skolnik, Jeffrey M, Rubin, Eric H, Smith, Paul D, Huang, Pearl, Learoyd, Maria, Shannon, Keith A, Morosky, Anne, Tetteh, Ernestina, Jou, Ying-Ming, Papadopoulos, Kyriakos P, Moreno, Victor, Kaiser, Brianne, Yap, Timothy A, Yan, Li, de Bono, Johann S

“…KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244;…”
Get full text

Epothilones: Mechanism of Action and Biologic Activity by GOODIN, Susan, KANE, Michael P, RUBIN, Eric H

“…Drugs that target microtubules are among the most commonly prescribed anticancer therapies. Although the mechanisms by which perturbation of microtubule…”
Get full text

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors by Tan, Antoinette R, Rubin, Eric H, Walton, Diana C, Shuster, Dale E, Wong, Y Nancy, Fang, Fang, Ashworth, Simon, Rosen, Lee S

“…Purpose: To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of eribulin mesylate (E7389), a halichondrin B…”
Get full text

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely by Day, Daphne, Monjazeb, Arta M, Sharon, Elad, Ivy, S Percy, Rubin, Eric H, Rosner, Gary L, Butler, Marcus O

“…Not until the turn of this century has immunotherapy become a fundamental component of cancer treatment. While monotherapy with immune modulators, such as…”
Get full text

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor by Iwamoto, Marian, Friedman, Evan J., Sandhu, Punam, Agrawal, Nancy G. B., Rubin, Eric H., Wagner, John A.

“…Purpose Vorinostat is a histone deacetylase inhibitor that has demonstrated preclinical activity in numerous cancer models. Clinical activity has been…”
Get full text

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial by HERBST, Roy S, MADDOX, Anne-Marie, OCHS, Judith, MUCCI LORUSSO, Patricia, ROTHENBERG, Mace L, SMALL, Eric J, RUBIN, Eric H, BASELGA, Jose, ROJO, Federico, WAUN KI HONG, SWAISLAND, Helen, AVERBUCH, Steven D

“…To investigate safety, tolerability, dose-related pharmacologic properties, and pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmacueticals,…”
Get full text

Mechanisms of resistance to topoisomerase I-targeting drugs by Rasheed, Zeshaan A, Rubin, Eric H

“…DNA topoisomerases are a class of enzymes that alter the topology of DNA and are targets of several anticancer drugs. Camptothecins (CPTs) are a relatively new…”
Get full text

Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53 by Rajendra, Rajeev, Malegaonkar, Diptee, Pungaliya, Pooja, Marshall, Henderson, Rasheed, Zeshaan, Brownell, James, Liu, Leroy F, Lutzker, Stuart, Saleem, Ahamed, Rubin, Eric H

“…The human topoisomerase I- and p53-binding protein topors contains a highly conserved, N-terminal C3HC4-type RING domain that is homologous to the RING domains…”
Get full text

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel by FETTERLY, Gerald J, GRASELA, Thaddeus H, RUBIN, Eric H, TAN, Antoinette R, SHERMAN, Jeffrey W, DUL, Jeanne L, GRAHN, Amy, LECOMTE, Diane, FIEDLER-KELLY, Jill, DAMJANOV, Nevena, FISHMAN, Mayer, KANE, Michael P

“…Purpose: To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of liposome-entrapped paclitaxel easy-to-use…”
Get full text

Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors by TAN, Antoinette R, MOORE, Dirk F, HIDALGO, Manuel, DOROSHOW, James H, POPLIN, Elizabeth A, GOODIN, Susan, MAURO, David, RUBIN, Eric H

“…Purpose: Previous studies of cetuximab pharmacokinetics did not fully characterize its elimination phase. The purpose of this trial was to evaluate the…”
Get full text

A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer by RUBIN, Eric H, AGRAWAL, Nancy G. B, WAGNER, John A, IWAMOTO, Marian, FRIEDMAN, Evan J, SCOTT, Pamela, MAZINA, Kathryn E, SUN, Linda, LIHONG DU, RICKER, Justin L, FRANKEL, Stanley R, GOTTESDIENER, Keith M

“…Purpose: This phase I study, conducted in advanced-stage cancer patients, assessed the safety and tolerability of oral vorinostat (suberoylanilide hydroxamic…”
Get full text

A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer by Munster, Pamela N, Rubin, Eric H, Van Belle, Simon, Friedman, Evan, Patterson, Jaclyn K, Van Dyck, Kristien, Li, Xiadong, Comisar, Wendy, Chodakewitz, Jeffery A, Wagner, John A, Iwamoto, Marian

“…Purpose: This dedicated QTc phase I study, conducted in advanced-stage cancer patients, assessed the effect of a single supratherapeutic dose (800 mg) of…”
Get full text

Phase I Dose-Finding Study of Weekly Single-Agent Patupilone in Patients With Advanced Solid Tumors by RUBIN, Eric H, ROTHERMEL, John, TESFAYE, Fisseha, TIANLING CHEN, HUBERT, Martine, HO, Yu-Yun, HSU, Chyi-Hung, OZA, Amit M

“…To evaluate the safety and maximum-tolerated dose (MTD) of weekly patupilone, a natural epothilone B, in patients with advanced solid tumors. Patients were…”
Get full text

The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development by Rubin, Eric H, Anderson, Keaven M, Gause, Christine K

“…Successful completion of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial, reported in this issue of Cancer…”
Get more information

Adaptive phase 2/3 designs for oncology drug development – Time to hedge by Chen, Cong, Rubin, Eric H.

“…Randomized-controlled Phase 2 trials are routinely skipped in oncology drug development in favor of directly going to confirmatory Phase 3 after…”
Get full text

Ubiquitination by TOPORS Regulates the Prostate Tumor Suppressor NKX3.1 by Guan, Bin, Pungaliya, Pooja, Li, Xiang, Uquillas, Carlos, Mutton, Laura N., Rubin, Eric H., Bieberich, Charles J.

“…The NKX3.1 gene located at 8p21.2 encodes a homeodomain-containing transcription factor that acts as a haploinsufficient tumor suppressor in prostate cancer…”
Get full text

Finding the Right Dose for Cancer Therapeutics—Can We Do Better? by Rubin, Eric H, Anderson, Keaven M

“…Unlike other diseases, dose-selection for cancer therapeutics is often based on the maximum-tolerated dose in phase 1 studies involving relatively few…”
Get full text